Wednesday, March 21, 2018

Pascal Biosciences Inc. - PAS.v

Pascal Biosciences Inc. - PAS.v was founded in 2013 in Vancouver, based on discovery research at UBC. Pascal is a biotechnology company focused on harnessing the body’s immune system to fight cancer. Our mission is to discover and develop innovative therapeutics that empower the immune system to help patients suffering from life-threatening diseases.
On March 19, 2018 the company released News

The TSX Venture Exchange has accepted for filing documentation with respect to a non-brokered private placement announced Feb. 23, 2018, and March 8, 2018.

Number of shares: 12,875,000 shares
Purchase price: 40 cents per share
Warrants: 12,875,000 share purchase warrants to purchase 12,875,000 shares
Warrant exercise price: 60 cents for a one-year period, subject to an acceleration clause
Number of placees: 41 placees
Total pro group involvement: 3,595,000 (four placees)
_______________________________________
On February 21, 2018 the Company released News

Pascal Biosciences Inc. (TSX.V:PAS) today announced the Company has discovered certain cannabinoids that enhance the immunogenicity of tumor cells, rendering them more susceptible to recognition by the immune system. This discovery is important because the leading class of new cancer fighting agents, termed “checkpoint inhibitors”, activates the immune system to destroy cancer cells. Enhancing recognition of cancer cells with cannabinoids may greatly improve the efficacy of this drug class. Cannabinoids are the chemical compounds which give the cannabis plant its medicinal properties with over 100 different cannabinoids identified. There is a growing body of research demonstrating the effectiveness of cannabinoids in the treatment of cancer symptoms, including nausea, appetite enhancement, and pain management. However, Pascal is the first to identify a mechanism in which cannabinoids may provide a direct benefit in immunotherapy.